Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
2019 ◽
Vol 145
(3)
◽
pp. 857-868
◽
2016 ◽
Vol 34
(15_suppl)
◽
pp. 11505-11505
◽
Keyword(s):
Keyword(s):
2011 ◽
Vol 54
(6)
◽
pp. 1896-1902
◽
2001 ◽
Vol 19
(16)
◽
pp. 3660-3668
◽
2017 ◽
Vol 18
(8)
◽
pp. 596-605
◽